BACKGROUND Cardiac troponin is an independent predictor of cardiovascular mortality in individuals without
years revealed that the risk reduction persisted long term (2) . This and other similar trials established the benefits of intervention in asymptomatic high-risk subjects (3, 4) , but debate continues over the merits of drug therapy in the wider primary prevention setting (5) (6) (7) . One approach to resolve this issue has been the search for biomarkers that enhance risk prediction.
Cardiac troponin is a specific marker of myocardial injury and an independent predictor of cardiovascular mortality in patients with and without cardiovascular disease (8) (9) (10) (11) (12) (13) (14) . Novel high-sensitivity assays can now accurately measure plasma cardiac troponin I concentrations in everyone. Higher troponin concentrations may reflect subclinical coronary artery disease and identify those at greatest risk who could benefit from targeted preventative therapies. The aims of this study were to determine whether cardiac troponin I concentrations could predict future coronary events, be modified by statins, and assess response to therapy in WOSCOPS.
METHODS
STUDY POPULATION. WOSCOPS randomized 6,595 men ages 45 to 64 years with moderate hypercholesterolemia (LDL cholesterol concentrations 152 to 228 mg/dl) and no prior history of myocardial infarction to receive placebo or pravastatin 40 mg/day. The design and conduct of the study have been described elsewhere (1, 15) . The study exclusion criteria are reported in full in the Online Appendix. Plasma was obtained before randomization and at 1 year, and was stored at -80 C. For the present analysis, we identified all participants with sufficient stored plasma at both time points. As a result, 3,318 of the 6,595 study participants were included. The research ethics committee of the University of Glasgow and all participating centers approved the trial design, and the participants provided written informed consent.
TROPONIN ASSAY. Cardiac troponin I concentrations in stored plasma were determined at baseline and at 1 year using the ARCHITECT STAT high-sensitive troponin I assay (Abbott Laboratories, Abbott Park, Illinois). The limit of detection is 1.2 ng/l, and the interassay coefficient of variation is <10% at 4.7 ng/l.
The upper reference limit or 99th-centile value is 34 ng/l in men (16) . All samples underwent centrifugation twice (3,000 relative centrifugal force for 10 min) to ensure samples were visibly homogeneous according to the manufacturer's instructions.
CLINICAL OUTCOMES AND RECORD LINKAGE. The primary outcome of the trial was a composite of nonfatal myocardial infarction (including nonhospitalized silent myocardial infarction) and death from coronary heart disease. During the formal trial period, patients were followed for an average of 4.9 years to determine the occurrence of the primary endpoint and other events, which were adjudicated by an endpoints committee (1, 15) . Additional follow-up for up to 15 years after randomization was available through the interrogation of records held by the National Health Service for Scotland (2) . Myocardial infarction events during the trial period included silent infarction, whereas those over the 15-year period were based only on hospitalization. Ford et al.
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RESULTS
Baseline characteristics of the 3,318 participants in this analysis were similar to the full study population (Online Table 1 ). Values are mean AE SD or n (%). *Symptoms consistent with angina on Rose questionnaire and minor ST-segment or T-wave abnormalities on resting 12-lead ECG defined by Minnesota codes (4-2, 4-3, 5-2, 5-3).
ACE ¼ angiotensin-converting enzyme; CHD ¼ coronary heart disease; ECG ¼ electrocardiogram; HDL ¼ high-density lipoprotein; LDL ¼ low-density lipoprotein; Q ¼ quarter.
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Participants were stratified into quarters of the baseline troponin concentration ( Table 1) 
Myocardial infarction or CHD death Cardiovascular death
Non-cardiovascular death Baseline troponin by quarters
P=0.890
Higher troponin concentrations at baseline were associated with increased risk of coronary heart disease (CHD) at both 5-and 15-year follow-up. Compared to the lowest quarter (#3.1 ng/l), patients in the highest quarter ($5.2 ng/l) were at the highest risk for nonfatal myocardial infarction or death from CHD at 5 and 15 years (hazard ratio: 2.27; 95% confidence interval: 1.42 to 3.65; and hazard ratio: 1.54; 95% confidence interval: 1.16 to 2.05, respectively; p < 0.001 for both). Cardiovascular death was also associated with baseline troponin concentration (p < 0.001), but noncardiovascular death was not (p ¼ 0.890).
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echocardiographic abnormalities (minor ST-segment and T-wave abnormalities) (Online Table 2 ).
BASELINE TROPONIN AND RISK OF CORONARY
HEART DISEASE EVENTS. Higher troponin concentrations at baseline were associated with increased risk of coronary heart disease at both 5-and 15-year follow-up ( Figure 1 , Online Table 3 ). Compared to the lowest quarter (#3.1 ng/l), patients in the highest quarter ($5.2 ng/l) were at the highest risk for nonfatal myocardial infarction or death from coronary heart disease at 5 and 15 years (HR: 2.27; 95% CI:
1.42 to 3.65 and HR: 1.54; 95% CI: 1.16 to 2.05, respectively; p < 0.001 for both). All-cause mortality and cardiovascular death were also associated with baseline troponin concentration, but noncardiovascular death was not. In a sensitivity analysis, similar relationships were observed for the primary endpoint in 2,882 men without symptoms or signs of coronary heart disease at enrollment (Online Figure 1) .
In this subset of the original study, the HR for the Table 4 ). At 15 years, the absolute risk reduction in nonfatal myocardial infarction or death from coronary heart disease was greatest in the highest quarter (9.0%) compared to the lower three quarters (2.6% to 3.0%) (Online Figure 2) .
CHANGE IN TROPONIN AND LDL CHOLESTEROL
WITH TREATMENT. At 1 year, participants taking pravastatin had a greater reduction in troponin concentration (19%) (95% CI: 17% to 20%) than those receiving placebo (6%) (95% CI: 4% to 8%; p < 0.001) ( Figure 2 ). The absolute change in troponin concentration from baseline with pravastatin was 2.0 ng/l (interquartile range: 1.2 to 2.8 ng/l; p < 0.001).
Change in troponin concentration on treatment correlated weakly with change in LDL cholesterol (r ¼ 0.20; p < 0.001).
CHANGE IN TROPONIN AND CORONARY HEART
DISEASE RISK REDUCTION. After adjustment for multiple variables (including baseline troponin concentration, and baseline and change in LDL cholesterol), change in troponin concentration at 1 year was an independent predictor of nonfatal myocardial infarction or death from coronary heart disease at both 5 and 15 years in both treatment arms ( Table 2) .
To explore this relationship further, participants were divided into fifths based on the change in troponin concentration in the placebo group. There was a clear gradient of risk across change in troponin. In the placebo group, relative to the referent (middle) fifth, those in the top fifth (>26% increase) had a higher risk of the primary endpoint over 5 years, and those in Change in LDL Concentration, %
Placebo Pravastatin
Line of fit is a Pearson correlation (pravastatin group r ¼ 0.20; p < 0.001). The ellipses are prediction ellipses with 95% confidence interval under the assumption the samples are bivariate normal to display linear correlation. LDL ¼ low-density lipoprotein. Figure 3) .
DISCUSSION
We observed a strong, specific, and independent association between baseline and 1-year change in plasma troponin I concentration and the onset of coronary heart disease over 5 and 15 years in WOSCOPS. Troponin concentrations were reduced by pravastatin therapy, which doubled the number of men whose troponin fell by more than a quarter and were at the lowest risk for future coronary events.
Thus, pravastatin treatment caused similar relative risk reductions in each category of troponin change and increased the propensity for troponin concentrations to fall, leading to additive decrements in future risk that appeared to be independent of LDL cholesterol lowering. We conclude that highsensitivity cardiac troponin assays can be used to predict future risk of coronary heart disease and to assess response to statin therapy (Central Illustration).
Therefore, serial troponin measurements appear to have major potential to monitor risk and assess the impact of established or novel therapeutic interventions on future coronary heart disease risk.
Our analysis has a number of important and distinctive strengths that distinguish it from previous studies of troponin in coronary heart disease risk prediction. First, we evaluated plasma troponin concentration in a primary prevention setting rather than in populations that included patients with established coronary heart disease. Second, we had access to prolonged robust clinical follow-up of wellcharacterized participants over a 15-year period.
Third, we used the latest-generation high-sensitivity cardiac troponin I assay, which detected troponin in 99.8% of the study population. Finally, in addition to exploring associations with baseline troponin concentration, we were able to critically assess dynamic changes in troponin concentrations as part of a major randomized placebo-controlled trial of statin therapy.
In WOSCOPS, a number of biomarkers have been assessed for cardiovascular risk stratification (17) (18) (19) .
In previous analyses, C-reactive protein predicted both cardiovascular and noncardiovascular events (19) , whereas troponin is a specific biomarker for the *Subjects who experienced a major coronary event in the first year (i.e., before repeat troponin measurement) were excluded from these analyses. †Troponin concentrations were log-transformed. Hazard ratios are reported for a doubling of log troponin concentration at baseline or doubling in the ratio of log troponin concentration from baseline to 1 year. ‡Increments of 39 mg/dl of LDL and HDL cholesterol. Models also included nitrate consumption, body mass index, smoking status, history of hypertension, diabetes, and ECG abnormalities at baseline: none of these was a significant determinant of the endpoint of nonfatal myocardial infarction/CHD death.
CI ¼ confidence interval; HR ¼ hazard ratio; other abbreviations as in Table 1 .
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Interestingly, in contrast to recent studies of patients with established coronary heart disease (8), we found that troponin predicted fatal and nonfatal myocardial infarction rather than heart failure events. Similar associations were recently reported in individuals without cardiovascular disease who participated in the JUPITER (Justification for the Use of Statins in Primary Prevention) trial (20) . This finding likely reflects differences in the extent of coronary heart disease at enrollment, the use of concomitant therapies, and the low prevalence of heart failure events.
The association between troponin and coronary heart disease risk is nonlinear, with an apparent threshold at 5.2 ng/l that identifies those 2 to 3 times more likely to have a coronary event over 15 years. This is consistent with findings from other cohorts using the same assay (21), in which receiver-operating curve analysis identified a threshold of 6 ng/l in a randomized trial population with established coronary heart disease (14) and 7 ng/l in men who participated in the Scottish Heart Health Study (12) . Interestingly, troponin concentrations <5 ng/l also identify patients as low risk in the emergency department (21), and increasingly this approach is being used to rule out myocardial infarction in clinical practice. Primary prevention guidelines recommend statins for the prevention of cardiovascular disease in any individual with a 10-year estimated risk of a cardiovascular event >7.5% (22) . This approach has been widely debated, with the benefits and risks for the individual more evenly balanced (5-7). We believe cardiac troponin may help to better stratify those healthy individuals at risk for coronary heart disease who would benefit most from statin therapies and that this approach should be formally addressed in prospective trials.
We hypothesized that statin therapy would reduce cardiac troponin concentrations. However, the observations that a large majority of participants on pravastatin had lower troponin concentrations at 1 year and that this reduction correlated with the decrease in LDL cholesterol were unexpected. White et al. (23) reported that cardiac troponin concentrations were reduced with pravastatin in patients with coronary heart disease. However, troponin concentrations were measured by a contemporary sensitive assay and were undetectable in more than one-third of patients and were below the limit of analytical precision in the majority. As such, the assay had insufficient sensitivity to evaluate the relationship among pravastatin therapy, troponin concentration, and LDL cholesterol. In contrast, we used a novel high-sensitivity assay that was able to measure cardiac troponin in >99% of our study population. 
Greatest increase Greatest decrease
Hazard ratio (95% confidence intervals) with no change in placebo group (Q3) as referent
(Top) Nonfatal myocardial infarction or death from coronary heart disease (CHD) at 5 years in those taking pravastatin (orange) and placebo (blue) stratified into fifths by change in troponin concentration in the placebo group: Q1 ¼ >26% increase; Q2 ¼ 2% to 25% increase; Q3 ¼ 2% increase to 13% decrease; Q4 ¼ 13% to 27% decrease; Q5 ¼ $27%
decrease. (Middle) Twice as many participants were in the lowest-risk group (Q5), with >27% reductions in troponin concentration (645 vs. 320 on placebo; p < 0.001), and 30% fewer were in the highest-risk group (Q1) with >26% increase in troponin concentration (223 vs. 320 on placebo; p < 0.001). (Bottom) Using participants in the placebo group whose troponin concentrations were unchanged as a referent (Q3), hazard ratios for the primary outcome were determined for each fifth after adjustment for age, body mass index, heart rate, systolic blood pressure, diastolic blood pressure, high-density lipoprotein and low-density lipoprotein (LDL) cholesterol, symptoms of angina, diabetes, hypertension, family history of premature coronary heart disease, minor electrocardiographic abnormalities, nitrate use, and smoking status. The risk of the primary endpoint in participants taking pravastatin was 5-fold lower in those with the greatest reduction in troponin concentration (hazard ratio: 0.23; 95% confidence interval: 0.10 to 0.53) compared to those with the greatest increase in troponin concentration (hazard ratio:
1.08; 95% confidence interval: 0.53 to 2.21; p < 0.001 for trend) despite similar reductions in LDL cholesterol concentration (22% to 28%).
This allowed us to explore associations among change in troponin, LDL cholesterol, and coronary events. 
protocol. This is the most likely explanation for the apparently greater treatment effect in this study compared to the intention-to-treat risk reduction reported previously (8) . Our analysis was performed on samples stored for 20 years, and it is possible we underestimated the association between troponin and coronary heart disease events because of interference from the formation of fibrin microparticulates during storage. Although the effect of pravastatin on troponin concentrations was highly consistent across the study population, the absolute and relative reductions were modest at 2 ng/l and 19%, respectively.
Although assay precision is very good at concentrations below our median concentration of 4.1 ng/l (w10% coefficient of variation) (25) and even smaller changes in cardiac troponin concentration were strongly associated with coronary heart disease events across the study population, we acknowledge it will be more challenging to monitor changes accurately in individual patients. Changes in troponin concentration of 2 ng/l after initiation of statin therapy may be masked by other aspects of biological or analytical variability (26) . However, there are methodological approaches to reduce the former, for example, performing duplicate measurements 2 weeks apart, and novel technologies that enhance assay precision through single molecular counting that will minimize the latter (27) . Before this approach can be applied in clinical practice, prospective studies are needed to determine whether we can consistently quantify small changes in cardiac troponin I concentration in response to treatment in individuals.
CONCLUSIONS
Cardiac troponin I is an independent predictor of coronary heart disease events in middle-aged hyper- TRANSLATIONAL OUTLOOK: Further studies are needed to clarify the predictive value of high-sensitivity cardiac troponin I assays to identify persons at increased risk and assess whether other interventions that lower plasma troponin levels reduce the risk of coronary heart disease.
